BIMI International Medical Inc. Announces Subsidiary Phenix Bio Inc’s Appointment of Hong Kong, Taiwan, and Macau Exclusive Distributor
2023年10月30日 - 10:29PM
BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a
healthcare products and services provider today announced that its
subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a
Singapore company (“Hao Mu”), as its exclusive distributor
responsible for the distribution of Phenix’s 17 herbal supplements
in Hong Kong, Taiwan and Macau.
Pursuant to the terms of a sales agreement entered into on
October 29, 2023, Hao Mu must make annual purchases of at least $5
million in order to maintain its exclusive distributor status for
this territory.
Under the terms of this agreement, Phenix’s comprehensive
portfolio of high-quality herbal supplements will be made available
to consumers in Hong Kong, Taiwan and Macau through Hao Mu’s
well-established distribution channels and network.
“We are excited to extend our agreement with Hao Mu,” stated
Tiewei Song, CEO of BIMI. “Expanding our cooperation with Hao Mu
will allow us to materialize our vision of making top-tier herbal
supplements accessible to individuals throughout Hong Kong, Taiwan
and Macau.”
This extension of its partnership with Hao Mu evidences BIMI’s
commitment to deliver world-class healthcare solutions and services
to a broader global audience. Representatives from BIMI, Phenix,
and Hao Mu, including BIMI’s Chief of Staff, Mr. Symington Smith,
and Hao Mu’s Chief Executive Officer, Mr. Liu Yubao, attended a
signing ceremony held at BIMI’s headquarters in New York City.
Hao Mu was previously appointed as
Phenix’s exclusive distributor for the ten-member ASEAN countries.
If Hao Mu is successful in meeting its minimum annual purchase of
$5 million for each of its three territories, the ten-member ASEAN
countries, Mainland China, and Hong Kong, Taiwan and Macao, it will
result in minimum annual sales of $15 million or minimum aggregate
sales of $75 million for the next five years of Phenix’s
herbal supplements. No assurance can be given that Hao Mu will be
successful in reaching these annual minimums.
About BIMI International Medical Inc.BIMI
International Medical Inc. is a healthcare products and services
provider, offering a broad range of healthcare products and related
services in the U.S. and Asia. For more information, please visit
www.usbimi.com.
About Hao Mu Pte. LtdHao Mu Pte Ltd is a
service and distribution company in Singapore with a strong market
presence within the ASEAN region. It is dedicated to offering
top-quality products and services.
Safe Harbor StatementCertain matters discussed
in this news release are forward-looking statements that involve a
number of risks and uncertainties including, but not limited to,
the Company’s ability to achieve profitable operations, its ability
to continue to operate as a going concern, its ability to continue
to meet NASDAQ continued listing requirements, the effects of the
spread of COVID-19, the demand for the Company’s products and
services, general economic conditions and other risk factors
detailed in the Company’s annual report and other filings with the
United States Securities and Exchange Commission.
Investor Relations ContactInvestor Relations
Department of BIMI International Medical Inc.Email:
vinson@usbimi.comTel: +1 949 981 6274
BIMI International Medical (NASDAQ:BIMI)
過去 株価チャート
から 5 2024 まで 6 2024
BIMI International Medical (NASDAQ:BIMI)
過去 株価チャート
から 6 2023 まで 6 2024